Save the Children and GSK join forces to develop drugs for children in developing countriesBMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f3103 (Published 13 May 2013) Cite this as: BMJ 2013;346:f3103
- Susan Mayor
The charity Save the Children and the drug company GlaxoSmithKline have established a partnership to work together to develop drugs to treat some of the leading causes of deaths in children in developing countries.
The two organisations are working together to prioritise areas for research, plan projects, and share expertise and resources to accelerate the development and availability of drugs and technologies to improve the health of children.
For the first time a member of Save the Children has a place on a new paediatric research and development board to help plan projects for development, and GSK will work with the charity’s healthcare teams on the ground to reach children in remote areas.
“GSK is really engaging with us, focusing on the areas of greatest need and working jointly on projects in the world’s poorest countries,” explained Simon Wright, head of child survival at Save the Children. …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial